Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Insider and Institutional Ownership
62.6% of Tectonic Therapeutic shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 27.7% of Vitro Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Tectonic Therapeutic and Vitro Diagnostics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Tectonic Therapeutic | N/A | -41.05% | -37.33% |
Vitro Diagnostics | -524.96% | N/A | -131.27% |
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tectonic Therapeutic | 0 | 0 | 4 | 1 | 3.20 |
Vitro Diagnostics | 0 | 0 | 0 | 0 | 0.00 |
Tectonic Therapeutic currently has a consensus price target of $60.00, indicating a potential upside of 36.49%. Given Tectonic Therapeutic’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Tectonic Therapeutic is more favorable than Vitro Diagnostics.
Earnings and Valuation
This table compares Tectonic Therapeutic and Vitro Diagnostics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.17) | -8.50 |
Vitro Diagnostics | $1.76 million | N/A | -$5.36 million | ($2.19) | -0.18 |
Tectonic Therapeutic has higher earnings, but lower revenue than Vitro Diagnostics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Vitro Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Tectonic Therapeutic beats Vitro Diagnostics on 8 of the 13 factors compared between the two stocks.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
About Vitro Diagnostics
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.